Showing results (171-180 of 180) with videos related to
Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 180 results.
Breast Cancer (Dove Medical Press)|March 23, 2026
Endocrine Therapy versus Chemotherapy After CDK4/6 Inhibitor Progression in HR+/HER2- Metastatic Breast Cancer: A Multicenter Real-World Study from TurkeyCan Cangür, Büşra Bülbül, Irem Turgut Yeğen, et al.Pharmaceuticals (Basel, Switzerland)|June 1, 2023
Sorafenib Alleviates Inflammatory Signaling of Tumor Microenvironment in Precancerous Lung InjuriesBetul Cicek, Ahmet Hacimuftuoglu, Mehmet Kuzucu, et al.Molecular Medicine Reports|August 3, 2022
Effects of boric acid and potassium metaborate on cytokine levels and redox stress parameters in a wound model infected with methicillin‑resistant Staphylococcus aureusDemet Celebi, Ali Taghizadehghalehjoughi, Sumeyye Baser, et al.Elife|February 11, 2025
Multi-tissue network analysis reveals the effect of JNK inhibition on dietary sucrose-induced metabolic dysfunction in ratsHong Yang, Cheng Zhang, Woonghee Kim, et al.Journal of Molecular Neuroscience : MN|November 5, 2022
Cerebrolysin Alleviating Effect on Glutamate-Mediated Neuroinflammation Via Glutamate Transporters and Oxidative StressSeydanur Avci, Sukran Gunaydin, Neziha Senem Ari, et al.Nutrients|February 11, 2023
Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate KinaseUmberto Maria Battisti, Chunixa Gao, Fady Akladios, et al.Medical Oncology (Northwood, London, England)|January 17, 2025
Boric acid impedes glioblastoma growth in a rat model: insights from multi-approach analysisHasan Turkez, Fatih Alper, Cemil Bayram, et al.Life Sciences|December 29, 2022
Combined metabolic activators improve metabolic functions in the animal models of neurodegenerative diseasesHasan Turkez, Ozlem Altay, Serkan Yildirim, et al.Translational Neurodegeneration|January 26, 2023
Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trialBurak Yulug, Ozlem Altay, Xiangyu Li, et al.Brain Communications|January 16, 2025
Multi-omics characterization of improved cognitive functions in Parkinson's disease patients after the combined metabolic activator treatment: a randomized, double-blinded, placebo-controlled phase II trialBurak Yulug, Ozlem Altay, Xiangyu Li, et al.Pageof 18